Tezspire EoE Phase 3 Win Adds Incremental Indication, but Amgen Thesis Unchanged

What happened

Amgen and AstraZeneca announced positive top-line results from the Phase 3 CROSSING trial of Tezspire (tezepelumab) in eosinophilic esophagitis (EoE), meeting both co-primary endpoints and all key secondary endpoints with statistically significant and clinically meaningful improvements versus placebo maintained through week 52. This represents a third epithelial-driven inflammatory disease for Tezspire, suggesting the drug's mechanism has broad applicability beyond its approved severe asthma indication. While positive, EoE is a relatively small market compared to Amgen's core growth drivers like MariTide and larger inflammation franchises, and Tezspire will face existing competition such as Dupixent. From a filing-driven perspective, Amgen's near-term risks—policy-driven price cuts on ENBREL and Otezla, biosimilar erosion of Prolia/XGEVA, and elevated leverage—remain dominant over incremental pipeline wins like this. Therefore, this data is unlikely to materially alter the investment thesis, which currently views Amgen as fully valued with limited margin of safety.

Implication

Over the next 6–18 months, the primary drivers of Amgen's stock performance remain MariTide Phase 3 data, execution on 2026 guidance, and the pace of legacy product erosion, not niche indication expansions like Tezspire in EoE. While this success adds a modest revenue opportunity and reinforces the scientific platform, the competitive landscape and limited patient population cap its upside, and it does not offset the certainty of IRA price cuts beginning in 2026 and RANKL biosimilar competition. Investors should continue to monitor key catalysts such as MariTide Part 2 Phase 2 data and Horizon asset performance, as these carry far greater weight for the valuation. The risk-reward at current levels continues to skew negative given the premium multiple and operational headwinds, suggesting disciplined entry only on meaningful pullbacks or concrete evidence of obesity franchise de-risking. Therefore, we maintain our cautious stance, with re-assessment hinging on guidance revisions, MariTide updates, or a share price retreat to the mid-$290s.

Thesis delta

The positive Phase 3 results for Tezspire in EoE slightly enhance the long-term growth potential of Amgen's inflammation portfolio, adding a third potential indication that could support sustained revenue contributions. However, this development does not materially shift the core investment thesis: Amgen remains fully valued at ~$339 with significant near-term headwinds from drug pricing reform and biosimilars, and the primary value inflection still lies with MariTide and cardiometabolic assets. We view this as incremental positive news that may cushion downside in the inflammation segment but does not change the overall cautious risk-reward assessment.